Trial Profile
Neovascular Age-related Macular Degeneration: Intraocular Inflammatory Cytokines in the Non-responder to Ranibizumab Treatment
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary) ; Aflibercept
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- 09 Oct 2018 Status changed from active, no longer recruiting to completed.
- 04 Jan 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 22 Aug 2014 New trial record